TRICOM Poxviral-Based Vaccines for the Treatment of Cancer
TRICOM poxviral-based vaccines are novel “off-the-shelf” agents designed to generate a robust immune response against tumor-associated antigens, which are commonly expressed on tumor cells. In this chapter, we elucidate the science behind the development
- PDF / 6,359,606 Bytes
- 393 Pages / 439.42 x 683.15 pts Page_size
- 0 Downloads / 159 Views
vel Technologies for Vaccine Development
Novel Technologies for Vaccine Development
.
Igor S Lukashevich • Haval Shirwan Editors
Novel Technologies for Vaccine Development
Editors Igor S Lukashevich Department of Pharmacology and Toxicology University of Louisville Louisville, Kentucky USA
Haval Shirwan Institute for Cellular Therapeutics and Department of Microbiology and Immunology University of Louisville Louisville, Kentucky USA
ISBN 978-3-7091-1817-7 ISBN 978-3-7091-1818-4 (eBook) DOI 10.1007/978-3-7091-1818-4 Springer Wien Heidelberg New York Dordrecht London Library of Congress Control Number: 2014956266 © Springer-Verlag Wien 2014 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher’s location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. While the advice and information in this book are believed to be true and accurate at the date of publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein. Printed on acid-free paper Springer is part of Springer Science+Business Media (www.springer.com)
Introduction
At the beginning of the twenty-first century, the worldwide market for vaccines demonstrated a strong growth. Sales of innovative virus-like particles (VLP) vaccines, such as Prevnar against pneumococcal bacteria and Gardasil, the first preventive human papilloma virus cancer vaccines, contributed to this industry’s success. According to industry forecasts, sales of preventive and therapeutic vaccine products will continue to grow and provide a lucrative market in the coming years for the pharmaceutical industry. To keep this trend intact, the vaccine manufact
Data Loading...
